2021
Potential novel imaging targets of inflammation in cardiac sarcoidosis
Park J, Young BD, Miller EJ. Potential novel imaging targets of inflammation in cardiac sarcoidosis. Journal Of Nuclear Cardiology 2021, 29: 2171-2187. PMID: 34734365, DOI: 10.1007/s12350-021-02838-w.Peer-Reviewed Original ResearchMeSH KeywordsCardiomyopathiesFluorodeoxyglucose F18HumansInflammationMyocarditisPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSarcoidosisConceptsCardiac sarcoidosisFDG-PET imagingPositron emission tomographyF-fluorodeoxyglucose positron emission tomographyNon-caseating granulomatous inflammationGranulomatous inflammationHigh morbiditySarcoid granulomasInflammatory diseasesPathognomonic featuresInflammationEmission tomographySarcoidosisMolecular targetsImaging targetsImagingMorbidityGranulomasMortalityDiseaseCytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging
Young BD, Moreland H, Oatmen KE, Freeburg LA, Shahab Z, Herzog E, Miller EJ, Spinale FG. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. International Heart Journal 2021, 62: 21-164. PMID: 34544982, DOI: 10.1536/ihj.21-164.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCase-Control StudiesCytokinesEvaluation Studies as TopicFemaleFluorodeoxyglucose F18Heart DiseasesHumansImmunosuppressive AgentsInflammationMaleMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiddle AgedPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsReceptors, Interleukin-2Receptors, Tumor Necrosis FactorRisk AssessmentSarcoidosisSeverity of Illness IndexTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AConceptsTumor necrosis factorSoluble cytokine receptorsCardiac sarcoidosisCS patientsMatrix metalloproteinasePlasma MMP-9 levelsFluorodeoxyglucose positron emission tomographyPlasma tumor necrosis factorAnti-inflammatory regimensBiopsy-confirmed sarcoidosisReferent control valuesSarcoidosis disease activityVascular endothelial growth factor receptorHeart failure therapySoluble TNF receptorsEndothelial growth factor receptorMMP-9 levelsSpecific inflammatory pathwaysFDG-PET imagingEndogenous MMP inhibitorsCytokine receptorsPositron emission tomographyCytokine receptor profilesGrowth factor receptorSIL-2R
2020
Complex cellular physiology underlies the use of FDG-PET imaging in investigating post-infarction remodeling
Miller EJ. Complex cellular physiology underlies the use of FDG-PET imaging in investigating post-infarction remodeling. Journal Of Nuclear Cardiology 2020, 27: 532-533. PMID: 31907858, DOI: 10.1007/s12350-019-02008-z.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsFluorodeoxyglucose F18InflammationMyocardial InfarctionPositron-Emission TomographyRadiopharmaceuticalsSwine
2019
Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis
Alvi RM, Young BD, Shahab Z, Pan H, Winkler J, Herzog E, Miller EJ. Repeatability and Optimization of FDG Positron Emission Tomography for Evaluation of Cardiac Sarcoidosis. JACC Cardiovascular Imaging 2019, 12: 1284-1287. PMID: 30846271, DOI: 10.1016/j.jcmg.2019.01.011.Peer-Reviewed Original ResearchUsing FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis
Sharp MB, Soufer A, Abdelmessih M, Rosenfeld LE, Baldassarre LA, Miller EJ. Using FDG-PET to guide targeted cardiac magnetic resonance imaging in patients with suspected cardiac sarcoidosis. Journal Of Nuclear Cardiology 2019, 27: 688-690. PMID: 30737635, DOI: 10.1007/s12350-019-01640-z.Peer-Reviewed Original Research
2018
A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology
Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, Jaber WA, Russell R, Gimelli A, Rouzet F, Hacker M, Gheysens O, Plein S, Miller EJ, Dorbala S, Donal E, Group D. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Journal Of Nuclear Cardiology 2018, 25: 298-319. PMID: 29043557, DOI: 10.1007/s12350-017-1043-4.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyCardiologyCardiomyopathiesDiagnostic ImagingEchocardiographyEuropeFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedInflammationMyocardial Perfusion ImagingNuclear MedicinePositron-Emission TomographyPrognosisRadionuclide ImagingReproducibility of ResultsSarcoidosisSocieties, MedicalTomography, X-Ray ComputedUnited StatesEstablishing an Evidence-Based Method to Diagnose Cardiac Sarcoidosis
Miller EJ, Culver DA. Establishing an Evidence-Based Method to Diagnose Cardiac Sarcoidosis. Circulation Cardiovascular Imaging 2018, 11: e007408. PMID: 29335273, DOI: 10.1161/circimaging.117.007408.Peer-Reviewed Original Research
2017
Diagnosis of extensive myocardial infiltration by diffuse large B-cell lymphoma using 18F-fluorodeoxyglucose positron emission tomography (18-FDG PET)
Higgins AY, Taylor EP, Baldassarre LA, Miller EJ, Rosenfeld LE. Diagnosis of extensive myocardial infiltration by diffuse large B-cell lymphoma using 18F-fluorodeoxyglucose positron emission tomography (18-FDG PET). Journal Of Nuclear Cardiology 2017, 25: 1869-1871. PMID: 29116563, DOI: 10.1007/s12350-017-1099-1.Peer-Reviewed Case Reports and Technical NotesJoint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, White ES, Borges-Neto S, Di Carli MF, Gropler RJ, Ruddy TD, Schindler TH, Blankstein R. Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. Journal Of Nuclear Cardiology 2017, 24: 1741-1758. PMID: 28770463, DOI: 10.1007/s12350-017-0978-9.Peer-Reviewed Original ResearchJoint SNMMI–ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, White ES, Borges-Neto S, Di Carli MF, Gropler RJ, Ruddy TD, Schindler TH, Blankstein R, GROUP N, Bateman T, Cerqueira M, Dilsizian V, Heller G, Moller D, Osborne M, Sadeghi M, Soman P. Joint SNMMI–ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal Of Nuclear Medicine 2017, 58: 1341-1353. PMID: 28765228, PMCID: PMC6944184, DOI: 10.2967/jnumed.117.196287.Peer-Reviewed Original Research
2016
The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis
Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. Journal Of Nuclear Cardiology 2016, 24: 413-424. PMID: 27457527, DOI: 10.1007/s12350-016-0490-7.Peer-Reviewed Original ResearchConceptsFDG PET/CTPET/CTFDG uptakeCardiac sarcoidosisFDG PET/CT studiesPET/CT studiesImmunosuppressive treatmentCardiac inflammationPartial responseComplete resolutionImproved outcomesSUV thresholdImmunosuppressionFDG responseCT studiesPatientsCTSarcoidosisFurther studiesQuantitative changesUptakeResponseInflammationSUVmaxCMV
2015
Quantifying FDG uptake to diagnose cardiac device infections: When and how should we do it?
Blankstein R, Miller EJ. Quantifying FDG uptake to diagnose cardiac device infections: When and how should we do it? Journal Of Nuclear Cardiology 2015, 23: 1467-1469. PMID: 26494648, DOI: 10.1007/s12350-015-0293-2.Peer-Reviewed Original Research
2014
Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, Govender P, Ruberg FL, Miller EJ. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. Journal Of Nuclear Cardiology 2014, 21: 925-939. PMID: 24879453, DOI: 10.1007/s12350-014-9901-9.Peer-Reviewed Original ResearchMeSH KeywordsFemaleFluorodeoxyglucose F18Heart DiseasesHumansImage EnhancementImage Interpretation, Computer-AssistedMaleMiddle AgedMultimodal ImagingMyocardial Perfusion ImagingPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsRetrospective StudiesSarcoidosisSensitivity and SpecificityTomography, X-Ray ComputedConceptsFDG PET/CTPET/CTCardiac sarcoidosisStandardized uptake valueMyocardial perfusion imagingClinical eventsPerfusion imagingCardiac FDG PET/CTAdverse clinical eventsOnly independent predictorNegative control studyCS correlatesImmunosuppressive treatmentPrednisone treatmentImmunosuppression treatmentIndependent predictorsFDG uptakeOncologic indicationsPerfusion defectsNegative studiesRepeat examinationLow EFUptake valueControl studyMultivariate analysis